NasdaqGS - Nasdaq Real Time Price USD

Ascendis Pharma A/S (ASND)

132.49 -0.97 (-0.72%)
As of 11:34 AM EDT. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
329,023.00
266,718.00
51,174.00
7,778.00
6,953.00
Cost of Revenue
47,343.00
44,395.00
12,137.00
3,523.00
--
Gross Profit
281,680.00
222,323.00
39,037.00
4,255.00
6,953.00
Operating Expense
642,681.00
677,864.00
600,851.00
456,047.00
337,573.00
Operating Income
-361,001.00
-455,541.00
-561,814.00
-451,792.00
-330,620.00
Net Non Operating Interest Income Expense
-136,089.00
-27,208.00
-23,256.00
-3,219.00
-106.00
Other Income Expense
4,036.00
8,605.00
7,253.00
71,067.00
-88,448.00
Pretax Income
-493,054.00
-474,144.00
-577,817.00
-383,944.00
-419,174.00
Tax Provision
8,514.00
7,303.00
5,377.00
-367.00
-219.00
Net Income Common Stockholders
-501,568.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Diluted NI Available to Com Stockholders
-501,568.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Basic EPS
-8.87
-8.55
-10.40
-7.00
-8.28
Diluted EPS
-8.87
-8.55
-10.40
-7.00
-8.28
Basic Average Shares
56,484.89
56,287.06
56,071.79
54,771.76
50,616.53
Diluted Average Shares
56,484.89
56,287.06
56,071.79
54,771.76
50,616.53
Total Operating Income as Reported
-361,001.00
-455,541.00
-561,814.00
-451,792.00
-330,620.00
Total Expenses
690,024.00
722,259.00
612,988.00
459,570.00
337,573.00
Net Income from Continuing & Discontinued Operation
-501,568.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Normalized Income
-517,768.00
-508,031.20
-607,911.97
-442,543.97
-340,070.46
Interest Income
-24,703.00
16,857.00
7,426.00
692.00
1,812.00
Interest Expense
111,386.00
44,065.00
30,682.00
3,911.00
1,918.00
Net Interest Income
-136,089.00
-27,208.00
-23,256.00
-3,219.00
-106.00
EBIT
-381,668.00
-430,079.00
-547,135.00
-380,033.00
-417,256.00
EBITDA
-362,826.00
-411,168.00
-529,177.00
-364,642.00
-407,808.00
Reconciled Cost of Revenue
47,343.00
44,395.00
12,137.00
3,523.00
--
Reconciled Depreciation
18,842.00
18,911.00
17,958.00
15,391.00
9,448.00
Net Income from Continuing Operation Net Minority Interest
-501,568.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Total Unusual Items Excluding Goodwill
27,000.00
27,000.00
24,950.00
59,026.00
-78,924.00
Total Unusual Items
27,000.00
27,000.00
24,950.00
59,026.00
-78,924.00
Normalized EBITDA
-389,826.00
-438,168.00
-554,127.00
-423,668.00
-328,884.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
10,800.00
415.80
232.04
59.03
-39.46
12/31/2020 - 1/28/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCVX Vaxcyte, Inc.
65.01
-0.28%
 
LEGN Legend Biotech Corporation
43.57
+0.76%
 
ARGX argenx SE
369.74
-1.31%
 
GMAB Genmab A/S
28.77
-0.24%
 
BPMC Blueprint Medicines Corporation
106.54
-0.15%
 
KRYS Krystal Biotech, Inc.
155.60
+0.54%
 
CYTK Cytokinetics, Incorporated
58.00
-6.60%
 
KROS Keros Therapeutics, Inc.
54.24
-0.06%
 
APGE Apogee Therapeutics, Inc.
53.56
+0.64%
 
BGNE BeiGene, Ltd.
162.60
+0.91%